

# Evaluation of the efficacy and safety of intravenous remdesivir in patients with severe COVID-19: study protocol for a phase 3 randomized, placebo-controlled, multicentre trial

Trials

21, 422

DOI: [10.1186/s13063-020-04352-9](https://doi.org/10.1186/s13063-020-04352-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Remdesivir and COVID-19 – Authors' reply. <i>Lancet</i> , The, 2020, 396, 954.	6.3	1
2	Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1841.	2.2	11
4	A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. <i>Cell</i> , 2020, 181, 223-227.	13.5	662
5	An overview on the use of antivirals for the treatment of patients with COVID19 disease. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 45-59.	1.9	4
6	Review of registered clinical trials for the treatment of COVID-19. <i>Drug Development Research</i> , 2021, 82, 474-493.	1.4	26
7	Building a hemodiafiltration system from readily available components for continuous renal replacement therapy under disasters and pandemics: preparing for an acute kidney injury surge during COVID-19. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 93-96.	1.0	2
8	Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 27-36.	1.5	28
9	Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: A meta-analysis. <i>Turkish Journal of Emergency Medicine</i> , 2021, 21, 43.	0.3	11
10	A crystallography-based investigation of weak interactions for drug design against COVID-19. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 7261-7270.	1.3	26
11	Immune dysregulation and system pathology in COVID-19. <i>Virulence</i> , 2021, 12, 918-936.	1.8	74
12	Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19. <i>BMC Nephrology</i> , 2021, 22, 52.	0.8	34
13	Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2. <i>Journal of Structural Biology</i> , 2021, 213, 107690.	1.3	8
14	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <i>European Journal of Pharmacology</i> , 2021, 895, 173890.	1.7	86
15	COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 357-360.	0.8	48
16	Ten things you need to know about intensive care unit management of mechanically ventilated patients with COVID-19. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1293-1302.	1.0	12
17	Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study. <i>Infectious Diseases of Poverty</i> , 2021, 10, 53.	1.5	13
18	Coronavirus Disease 2019: An Overview of the Complications and Management. , 0, , 1-28.		1
19	Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 665-706.	0.4	12

#	ARTICLE	IF	CITATIONS
20	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	1.6	75
21	Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 104, 107851.	1.3	29
22	Pharmacological Effects of Selected Medicinal Plants and Vitamins Against COVID-19. , 2021, 7, .		4
25	The immunological response among COVID-19 patients with acute respiratory distress syndrome. <i>Journal of Infection and Public Health</i> , 2021, 14, 954-959.	1.9	3
26	Innate lymphoid cells (ILC) in SARS-CoV-2 infection. <i>Molecular Aspects of Medicine</i> , 2021, 80, 101008.	2.7	10
27	Remdesivir for the treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD014962.	1.5	90
28	Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far. <i>Current Drug Research Reviews</i> , 2022, 14, 11-19.	0.7	2
29	Theaflavin-3-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir. <i>Drug Research</i> , 2021, 71, 462-472.	0.7	8
30	Experimental Pharmacotherapy for COVID-19: The Latest Advances. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 1-13.	1.5	22
31	The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. <i>Briefings in Bioinformatics</i> , 2021, 22, 742-768.	3.2	29
32	Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0243705.	1.1	62
33	The COVID-19 Pandemic - A Global Public Health Crisis: A Brief Overview Regarding Pharmacological Interventions. <i>Pesquisa Brasileira Em Odontopediatria E Clinica Integrada</i> , 2020, 20, .	0.7	9
34	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9775.	1.8	40
35	Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review. <i>Borneo Journal of Pharmacy</i> , 2020, 3, 90-102.	0.1	1
38	SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 193, 1249-1273.	3.6	19
39	Comparative therapeutic efficiency of remdesivir in COVID in a tertiary care center. <i>APIK Journal of Internal Medicine</i> , 2021, 9, 244.	0.1	0
40	Transcriptomic Signatures and Immunomodulatory Treatments for COVID-19 Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
44	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 8-19.	2.5	5

#	ARTICLE	IF	CITATIONS
45	The Petasites hybridus CO2 Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro. <i>Viruses</i> , 2022, 14, 106.	1.5	4
46	Pharmacological treatment of COVID-19: an opinion paper. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 115-130.	0.5	47
47	Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. <i>Biomedicines</i> , 2022, 10, 437.	1.4	5
48	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. <i>Pathogens</i> , 2022, 11, 368.	1.2	23
50	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
51	Evaluation of efficacy and safety of Qiangzhu-qinggan formula as an adjunctive therapy in adult patients with severe influenza: study protocol for a randomized parallel placebo-controlled double-blind multicenter trial. <i>Trials</i> , 2021, 22, 955.	0.7	4
52	4â€™-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review. <i>F1000Research</i> , 0, 11, 410.	0.8	3
53	Remdesivir for the treatment of COVID-19. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	17
54	The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on SARS-CoV-2 Patients. <i>Current Drug Discovery Technologies</i> , 2023, 20, .	0.6	0